TC Biopharm Stock Scheduled to Reverse Split on Monday, February 10th (NASDAQ:TCBP)

Shares of TC Biopharm (Holdings) Plc (NASDAQ:TCBP) are set to reverse split on Monday, February 10th. The 1-20 reverse split was announced on Wednesday, February 5th. The number of shares owned by shareholders will be adjusted after the market closes on Friday, February 7th.

TC Biopharm Price Performance

Shares of NASDAQ TCBP opened at $0.25 on Thursday. The company’s fifty day simple moving average is $0.43 and its 200 day simple moving average is $2.40. TC Biopharm has a 12-month low of $0.21 and a 12-month high of $26.16.

Wall Street Analyst Weigh In

Separately, HC Wainwright cut their price objective on shares of TC Biopharm from $5.60 to $2.40 and set a “buy” rating on the stock in a research report on Friday, December 6th.

TC Biopharm Company Profile

TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on the development of immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an allogeneic unmodified gamma-delta T cell therapy product under Phase 2/3 trails for the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat viral infections as well as cancers.